The role of pembrolizumab in relapsed/refractory primary mediastinal large B-cell lymphoma

Sarah Tomassetti, Robert Chen and Savita Dandapani

Abstract: Primary mediastinal large B-cell lymphoma (PMBCL) is a subtype of diffuse large B-cell lymphoma (DLBCL). PMBCL comprises approximately 10% of DLBCLs, thus making it a rare variant of DLBCL. Cure rates for PMBCL with upfront regimens like DA-REPOCH exceed 90%. However, if there is a poor response to this first-line therapy, relapsed/refractory PMBCL (rrPMBCL) has limited treatment options. The historic trend is to treat rrPMBCL with salvage regimens commonly used for DLBCL followed by high-dose therapy and autologous stem cell transplant (HDT-ASCT); however, response rates to salvage therapy remain low and few patients are able to proceed to transplant. An interesting feature of PMBCL is that even though it is classified as a subtype of DLBCL, PMBCL actually shares many clinical, pathologic, and genetic features with classical Hodgkin lymphoma (cHL). For example, both frequently express program death ligand 1 and 2 (PD-L1/2), which is not seen in other mature B-cell lymphomas. The expression of PD-L1/2 in PMBCL makes PDL1 inhibitors, such as pembrolizumab, an attractive therapeutic target. Pembrolizumab is an effective and well-tolerated therapy now approved for a number of cancer types from advanced melanoma to relapsed/refractory cHL. There are now multi-institutional trials underway assessing the role of pembrolizumab in the treatment of rrPMBCL.

Keywords: pembrolizumab, primary mediastinal B-cell lymphoma

Introduction

Primary mediastinal B-cell lymphoma (PMBCL) is a newly recognized B-cell lymphoma currently classified as a subtype of diffuse large B-cell lymphoma (DLBCL). While no standard treatment of PMBCL has been established, with the use of therapy like DA-REPOCH, the 5-year event-free survival (EFS) and overall survival (OS) exceed 90%. However, for those who either do not respond to frontline therapy or relapse, prognosis is dismal with OS at 2 years of 15%.1 Historically, the approach to relapsed/refractory PMBCL (rrPMBCL) has been similar to that of relapsed/refractory DLBCL with treatment regimens such as DHAP (dexamethasone, cytarabine, cisplatin), ESHAP (etoposide, methylprednisolone, cytarabine, platinum agent), GDP (gemcitabine, dexamethasone, cisplatin), and mini-beam (carmustine, etoposide, cytarabine, melphalan), but with unacceptably low response rates of 0–25%.1,2 PMBCL shares many features with classical Hodgkin lymphoma (cHL) including expression of program death ligands 1 and 2 (PD-L1/2). The binding of PD-L1/2 to its receptor on T-cells, program cell death 1 (PD-1), negatively regulates T-cell-mediated immune events and provides a method for tumor cells to evade the antigen-specific T-cell immunologic response. Pembrolizumab, a PD-1 inhibitor, binds PD-1 and blocks the activation of PD-1 and PD-L1/2 signaling. It is approved for the treatment or relapsed/refractory cHL. Given the expression of PD-L1/2 on PMBCL cells and its known efficacy in cHL, pembrolizumab is now being assessed in patients with rrPMBCL with promising results and good tolerability. In this article we review the current understanding of

(End of text)
PMBCL and the emerging role of pembrolizumab as an effective therapy for rrPMBCL.

**Background**

PMBCL was first described in the 1980s as a mediastinal large cell lymphoma affecting young women with characteristic fibrosis and a propensity to invade surrounding structures such as the pleura, pericardium, and superior vena cava. \(^3\)–\(^7\) In 1994, it was recognized as its own entity by the revised European-American classification of lymphoid neoplasms. \(^8\) In 2008, it was included in the World Health Organization classification of lymphoid neoplasms under mature B-cell lymphomas. \(^9\) However, although it is classified as a subtype of mature B-cell lymphomas, it has unique clinical, pathologic, and genetic features that make it a unique entity of its own.

PMBCL comprises approximately 2–4% of non-Hodgkin lymphomas and 10% of DLBCLs. \(^10\) Unlike DLBCL, it is more common in women in their 30–40s. \(^11\),\(^12\) It is thought to be derived from medullary thymic B-cells. \(^13\) By histology it is characterized by a diffuse proliferation of medium to large B-cells with surrounding sclerosis. \(^14\) Clinically, it presents as a bulky mediastinal mass with tumors greater than 10 cm found in 70–80% of patients at presentation. \(^15\) Pleural or pericardial effusions are not uncommon and up to one-half of patients show signs or symptoms of superior vena cava syndrome. \(^4\)–\(^6\),\(^15\) Bone marrow infiltration and extranodal sites of involvement are rare at presentation. \(^11\) However, at the time of recurrence, extranodal sites of disease are common and include areas such as the kidneys, adrenal glands, liver, ovaries, and central nervous system (CNS). \(^16\)

PMBCL is molecularly different from DLBCL. It expresses pan B-cell antigens CD19, CD20, CD22, and CD79α and B-cell transcription factors BOB1, OCT2, PAX5. \(^17\) However, it usually does not express surface immunoglobulins like other DLBCLs. \(^7\),\(^17\) Additionally, CD30 expression is seen in over 80% of PMBCL, but CD15 is usually absent. \(^18\) It has variable expression of bcl2 and bcl6, and in contrast with other subtypes of DLBCL, bcl2, bcl6, and myc rearrangements are usually absent. \(^19\) The differential diagnosis includes cHL and mediastinal grey zone lymphoma.

Although it is classified as a variant of DLBCL, it shares many common features with the cHL subtype, nodular sclerosing Hodgkin lymphoma (nSHL). \(^20\)–\(^22\) Both commonly present as a mediastinal mass in young adults. By histology both have variable numbers of malignant cells within an inflammatory infiltrate suggesting immune evasion by the tumor cells. The large B-cells in PMBCL may have round or lobulated nuclei with an abundant cytoplasm, which can sometimes resemble Hodgkin/Reed–Sternberg cells. \(^17\) Surface immunoglobulin expression is usually absent in both types of lymphomas. Additionally, as mentioned previously, PMBCL commonly expresses CD30, although weaker and more heterogeneously than cHL. \(^18\),\(^21\) In fact, gene expression profiling looking at signature genes expressed by HL and PMBCL showed that PMBCL shares one-third of its genes with nSHL. \(^21\) These signature genes were not expressed by other subtypes of DLBCL. \(^21\) A highly expressed gene that was common to both PMBCL and HL was PDL2. \(^21\)

**Frontline treatment of PMBCL**

Initially, the treatment of PMBCL consisted of anthracycline-based high intensity chemotherapy with consolidative radiation with overall response (OR) rates of greater than 60% after chemotherapy, which increased to greater than 80% after administration of consolidative radiation. \(^23\),\(^24\) However, concern for the long-term effects of radiation emerged. The increased risk of coronary artery disease and breast cancer in women have been well established in patients treated with radiation for HL and prompted the development of regimens such as DA-REPOCH (dose-adjusted rituximab, etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin) administered without radiation. \(^25\)–\(^27\) In the phase II, prospective study of 51 patients with newly diagnosed PMBCL given DA-REPOCH without routine consolidative radiation, the 5-year EFS and OS rates were 93% and 97% respectively. After follow up ranging from 10 months to 14 years, only 2 of the 51 patients (4%) had residual focal disease on positron emission tomography (PET)-computed tomography (CT). These two patients received radiation and were also subsequently disease-free. Similar results were seen in a retrospective study of 16 patients with PMBCL treated at Stanford with DA-REPOCH alone with a complete response (CR) rate of 100% at a median follow up of 37 months. \(^27\) Given that only two patients required radiation from both trials, it suggests that the use of DA-REPOCH may decrease the need for
radiotherapy. Future trials incorporating PET may help delineate when radiation will be beneficial or whether lower doses of consolidative radiation may help improve EFS in PMBCL.

**Treatment for relapsed/refractory PMBCL**

It is believed that patients with PMBCL who do not relapse after 18 months of initial treatment are likely cured, as relapse usually occurs within the first 12–18 months. Optimal therapy for relapsed/refractory disease has not been well defined. For localized relapse confined to mediastinum, local radiation can be curative. For nonlocalized relapse, second-line strategies have been similar to those used in DLBCL and include re-induction with noncross-resistant agents (such as rituximab, ifosfamide, carboplatin, etoposide (RICE), DHAP, or others) followed by consolidation high-dose therapy (HDT) and autologous stem cell transplant (ASCT). However, response rates to salvage therapies are unacceptably low. In a study of 99 patients with newly diagnosed PMBCL treated with doxorubicin-containing chemotherapy, 35% relapsed or had refractory disease. Of the 35%, none of the patients with primary refractory disease and only 22% of those with relapsed disease responded to salvage chemotherapy.

There are only a few small retrospective studies looking at ASCT in rrPMBCL. A study looked at 35 patients treated with high-dose cyclophosphamide, carmustine,etoposide (CBV) followed by ASCT. A total of 23 of the 35 patients had rrPMBCL (11 had relapsed disease and 12 had primary refractory disease). At the time of ASCT, 4 of the 11 patients with relapsed disease were chemotherapy-responsive. Of the 8 patients with refractory disease, 8 of the 12 patients remained refractory, 8 achieved a CR, and 2 achieved a partial response (PR). The 5-year progression free survival (PFS) for those with relapsed disease and refractory disease was 27% and 58% respectively. The strongest predictor of PFS was chemotherapy responsiveness immediately prior to transplantation. Patients with chemo-responsive disease had a 5-year PFS of 75% compared with 33% with chemo-resistant disease. A small retrospective study conducted in Japan included 44 patients with rrPMBCL treated with HDT followed by ASCT. In this study, the OR rate was 77% with 64% achieving a CR. The median follow up was 54 months. The 4-year OS and PFS were 70% and 61% respectively. For patients with relapsed disease compared with primary refractory disease, OS at 4 years was 73% and 65% respectively. Additionally, the 4-year OS and PFS was 80% and 69% respectively for those with chemo-sensitive disease compared with 50% and 45% respectively for those with chemorefractory disease.

Studies suggest that in comparison with DLBCL, fewer patients with rrPMBCL than DLBCL respond to salvage chemotherapy, but for those who do respond, the outcomes of ASCT in the relapsed setting may be similar. A retrospective study compared outcomes of salvage chemotherapy followed by ASCT in 37 patients with rrPMBCL with a control group of 143 patients with rrDLBCL. The OR rate to salvage chemotherapy (DHAP, ESHAP, GDP, and mini-Beam) was 25% for those with PMBCL and 48% for those with DLBCL. A total of 65% of patients with PMBCL and 34% of patients with DLBCL received a second line of salvage chemotherapy. However, although only 22% of patients with PMBCL and 50% of those with DLBCL were able to proceed to ASCT, there was no significant difference in the 2-year post-ASCT OS or PFS rates (67% and 53%, and 57% and 36% respectively).

Regardless of this, response rates of rrPMBCL patients to current salvage chemotherapy are unacceptably low and new therapeutic strategies are needed.

**Programmed cell death ligand expression in PMBCL**

As mentioned previously, cHL and PMBCL share many common characteristics. Both cHL and PMBCL have a similar gene expression profile and both harbor genetic alterations of chromosome 9p. Specifically, 9p24.1 has been shown to be amplified in 53–70% of PMBCL cases and 30–40% of cHL cases, but rarely in DLBCL. This region contains the genes for PD-1 ligands, PD-L1, and PD-L2, separated by 42 kilobases. In both PMBCL and cHL, amplification of 9p24.1 has been shown to be associated with both increased PD-L1/2 transcripts and cell-surface protein expression. Expression of PD-L1 is found in 30–80% of PMBCL cases and 70–87% of cHL and 31–57% of DLBCL express PD-L1. Additionally, the 9p24.1 chromosome has been
found to be rearranged in 20% of PMBCL cases.\textsuperscript{38} In another pathology study by Shi and colleagues, 72% of PMBCL cases expressed PD-L2 but only 3% of other DLBCL cases.\textsuperscript{36} PD-L1 and PD-L2 transcripts have been shown to be elevated in PMBCL regardless of whether the locus was rearranged or amplified suggesting alternative mechanisms of regulation.\textsuperscript{36,38} In normal cells, PD-1 ligand activation is induced by cytokine-mediated signaling activated by the Janus kinase 2/signal transducer and activator of transcription (JAK2/STAT) pathway.\textsuperscript{35} The JAK2/STAT pathway regulates the transcription of genes that influence both cell proliferation and apoptosis and has been implicated in the pathogenesis of a number of hematologic malignancies.\textsuperscript{42} JAK2 is also found within the 9p24.1 band, 322 kilobases upstream from the PD-L1 gene.\textsuperscript{35} It has been shown to also be co-amplified with the PD-L1/2 loci in both PMBCL and cHL cell lines.\textsuperscript{35,43} Amplification of JAK2 has been shown to be associated with increases JAK2 protein expression and activated (phosphorylated) JAK2 protein. Activated JAK2 protein further activates PD-L1/2 expression in PMBCL and cHL.\textsuperscript{35} JAK2 inhibition has been shown to specifically decrease PMBCL growth \textit{in vitro} and \textit{in vivo} suggesting another possible therapeutic target.\textsuperscript{44}

### Pembrolizumab background

PD-1 was first recognized in the early 1990s after it was found to be expressed by a T-cell hybridoma upon induction of apoptosis.\textsuperscript{45,46} The binding of PD-1 to its receptor, PD-L1, on dendritic cells and macrophages negatively regulates T-cell-mediated immune events.\textsuperscript{47–50} It was found that various tumor types express PD-L1, and that activation of PD-1/PD-L1 signaling serves as a method for tumor cells to evade the antigen-specific T-cell immunologic response.\textsuperscript{51,52} Thus, it was reasoned that the blocking of PD-1/PD-L1 signaling could be an effective cancer therapy. The results of several phase 1 studies looking at humanized monoclonal immunoglobulin (Ig)G4 antibodies to PD-1 and PD-L1 in solid tumors inspired the development of the first PD-1 inhibitors, nivolumab and pembrolizumab.\textsuperscript{53–55} Pembrolizumab is a humanized monoclonal IgG4 antibody to PD-1, which blocks binding to its ligands PD-L1 and PDL2. It was first approved for the treatment of advanced or metastatic melanoma in September 2014 based on the findings from the KEYNOTE-001 study.\textsuperscript{36} Since then, PD-1 and PD-L1 inhibitors have been approved for the treatment of a wide variety of malignancies from malignant melanoma to HL.\textsuperscript{56,57}

As previously discussed, classical Hodgkin Reed-Sternberg cells have been shown to express varying levels of PD-L1, while both the tumor-infiltrating T-cells and peripheral T-cell express high levels of PD-1.\textsuperscript{39,41,58} Nivolumab was the first PD-1 inhibitor to be approved for hematologic malignancies based on the findings from the CheckMate039 and CheckMate205 studies showing response rates of 87% and 66% respectively.\textsuperscript{59,60} Shortly thereafter, pembrolizumab was approved for the treatment of relapsed/refractory cHL in March 2017 based on the KEYNOTE-087 trial showing an OR rate of 69%.\textsuperscript{60}

### Pembrolizumab in relapsed/refractory PMBCL

The finding that PMBCL, like cHL, also express PD-1 ligands prompted an initial multicenter, international phase Ib study of pembrolizumab in patients with rrPMBCL (Keynote-013), which is currently ongoing.\textsuperscript{61} Eligible patients were those with relapsed/refractory PMBCL who had either relapsed after, or were ineligible for, ASCT. The first 11 of 19 patients enrolled in the trial received pembrolizumab at a dose of 10 mg per kg every 2 weeks. Subsequent pharmacokinetic and pharmacodynamics studies showed equivalence of pembrolizumab drug exposure with either weight-based or fixed dosing.\textsuperscript{62} Consequently, the subsequent eight patients received a fixed dose of pembrolizumab 200 mg every 3 weeks. Treatment was continued for up to 2 years, or until unacceptable toxicity or confirmed disease progression. Treatment response was assessed by PET CT at 6 and 12 weeks, and then every 9 weeks thereafter. Primary endpoints were safety and OR rate by investigator assessment. Secondary end points included CR, duration of response, and time to subsequent lymphoma therapy. Of the 19 patients enrolled, 17 patients were included in the efficacy analysis population (1 patient withdrew prior to receiving any doses and 1 patient did not receive the primary response assessment by time of data cutoff). The median age of patients was 30 years. A total of 72% were women. Patients were heavily pretreated with 61% having had received three or more prior lines of therapy and 33% having had prior ASCT. Overall, 41% (7/17) of patients responded. There were two patients that achieved a
CR, five patients achieved a PR, and six patients had stable disease (SD). A total of 81% of patients had an overall decrease in their target lesions. At a median follow up of 11 months, the median duration of response was not reached, and six of the seven responses were ongoing. None of the responders received an ASCT. Overall, 10 patients discontinued treatment (5 due to the progression of disease based on imaging, 4 due to clinical progression, and 1 due to physician decision). The two patients who responded reached the maximum 2 years of treatment before data cutoff and remained in remission. All patients with an objective response were alive at the time of data cutoff (Table 1).

Pembrolizumab was well tolerated. A total of 61% had treatment-related adverse events (TRAEs) that were mostly grade 1–2. Overall, six patients had serious adverse events, but none discontinued treatment due to adverse events. The most common TRAEs were hypothyroidism, diarrhea, nausea, fatigue, pyrexia, and decreased appetite. The only grade 3 adverse event was neutropenia, and the only grade 4 adverse event was veno-occlusive liver disease after allogeneic stem cell transplant (SCT), at which time the pembrolizumab had been discontinued. The only potential immune events were 1 grade 2 diarrhea and 1 grade 2 radiation pneumonitis. The positive results from this study prompted a global, multicenter, phase II trial (KEYNOTE-170) evaluating the efficacy of single-agent pembrolizumab in heavily pretreated rrPMBCL patients.

The KEYNOTE-170 trial is an ongoing, multicenter, phase II trial of patients with rrPMBCL. In this trial, patients must have either failed ASCT or have failed two or more prior lines of therapy and were ineligible for ASCT.63,64 Patients were treated with pembrolizumab 200 mg intravenously (IV) every 3 weeks. Treatment was continued until either unacceptable toxicity or documented disease progression. For those without toxicity or disease progression, it was continued for up to 2 years. The primary endpoint was the OR rate assessed by a blinded independent central review. Secondary endpoints included the OR rate by investigator review and adverse events.

A total of 49 patients were evaluable in the interim results with a median age of 33 years. Patients were heavily pretreated and had received a median of three prior lines of therapy. Overall, 70% of patients had chemorefractory disease and were thus not eligible for ASCT. Similar to the phase I study, the OR rate was 41% by blinded independent central review (38% by investigator assessment). At the time of data analysis, 14% achieved a CR, 28% achieved PR, and 10% had SD assessed by independent review. A total of 28% had progression of disease and 21% were not assessable for response evaluation. The median time to response was 2.9 months. At an average follow up of 6.6 months, median duration of response and OS were not reached. At 1 year, 62% were still alive. Of all patients, 59% were positive for PD-L1 (4% were negative and 37% were unknown). Of those who responded, 76% were positive for PD-L1 (3% were negative and 21% were unknown).

Pembrolizumab was well tolerated with 1 year OS of ~60%.63,64 Approximately 40% of patients had a response to pembrolizumab.63,64 There were adverse events with 25% serious and over 50% were treatment-related.63,64 Overall 35% experienced serious adverse events and 53% experienced TRAEs. Based on the positive results of this trial, in June 2018, pembrolizumab was granted accelerated approval by the United States Food and Drug Administration (US FDA) for use in rrPMBCL patients who have progressed after two or more lines of prior therapy.64 These studies both show OR rates of 41% with pembrolizumab salvage therapy. This is higher than the prior retrospective studies using regimens traditionally used for DLBCL (DHAP, ESHAP, GDP, and mini-beam), which have shown OR rates ranging from 0 to 25% in rrPMBCL patients.2,28,30 Although the PFS rates for rrPMBCL patients following ASCT can be as high as 67–80%, this has only been shown for those with chemotherapy-sensitive disease.28,30,31 The strongest predictor of PFS for ASCT was chemotherapy responsiveness immediately prior to transplantation.30 For those who do not respond to chemotherapy prior to ASCT, long-term disease-free survival rates range from 33% to 45%.30,31 Novel therapies for rrPMBCL are desperately needed as response rates to salvage regimens traditionally used in patients with DLBCL are unacceptably low.

Combination therapy with immune checkpoint inhibitors
Preclinical and clinical studies in both solid tumors and hematologic malignancies have suggested that...
### Table 1. Relapsed/refractory PMBCL treated with salvage regimen.

| Regimen                  | Phase | Number of Patients | Average number of prior lines of therapy | Patients with prior ASCT (%) | Prior RT (%) | ORR (%) | CR (%) | PR (%) | SD (%) | Reference |
|--------------------------|-------|--------------------|------------------------------------------|------------------------------|--------------|---------|--------|--------|--------|-----------|
| Pembrolizumab            | 1b    | 17                 | 33                                       | 61                           | 41           | 12      | 29     | 35     | 61     |           |
| Pembrolizumab            | 2     | 49                 | 3                                        | 30                           | 31           | 41      | 14     | 28     | 10     | 64        |
| Brentuximab vedotin      | 2     | 15                 | 53                                       | 60                           | 13           | 0       | 0      | 76     |        |           |

ASCT, autologous stem cell transplant; CR, complete response; ORR, overall response rate; PMBCL, primary mediastinal large B-cell lymphoma; PR, partial response; RT, radiotherapy; SD, stable disease.

### Table 2. Ongoing clinical trials utilizing pembrolizumab in PMBCL.

| Trial Intervention              | Phase | Title                                                                 | Line of Treatment | ClinicalTrials.gov identifier | Status; Estimated completion date |
|---------------------------------|-------|----------------------------------------------------------------------|-------------------|--------------------------------|----------------------------------|
| Pembrolizumab-RCHOP             | 1     | Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Diffuse Large B-cell Lymphoma or Grade 3b Follicular Lymphoma | First-line        | NCT02541565                    | Recruiting; November 2020         |
| Pembrolizumab and Tisagenlecleucel | 1   | Study of Tisagenlecleucel in Combination With Pembrolizumab in r/r Diffuse Large B-cell Lymphoma Patients (PORTIA) | Relapsed and/or refractory | NCT03630159                    | Recruiting; February 2023         |
| Pembrolizumab and Vorinostat    | 1     | Pembrolizumab and Vorinostat in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, or Hodgkin Lymphoma | Relapsed and/or refractory | NCT03150329                    | Recruiting; July 2019             |
| Pembrolizumab and Ibrutinib     | 1/1b  | Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma | Relapsed and/or refractory | NCT02950220                    | Active, not recruiting; December 2019 |
| Pembrolizumab, Dendritic Cell Therapy, and Cryosurgery | 1/2 | Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma | Relapsed and/or refractory | NCT03035331                    | Recruiting; December 2021         |
| Rituximab and Pembrolizumab     | 2     | Rituximab and Pembrolizumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma | Relapsed and/or refractory | NCT03401853                    | Recruiting; February 2021         |
| Pembrolizumab after Stem Cell Transplant | 2  | Pembrolizumab After ASCT for Hodgkin Lymphoma, DLBCL and T-NHL | Relapsed and/or refractory | NCT02362997                    | Recruiting; December 2022         |

NCT, ClinicalTrials.gov identifier; PMBCL, primary mediastinal large B-cell lymphoma.
combination immune checkpoint inhibitors and immune checkpoint inhibitors combined with other therapeutic agents may have synergistic effects. In relapsed or refractory HL (rrHL), the combination of nivolumab with brentuximab vedotin (BV) has shown an OR rate of 82–89% and a CR rate of 50–61%. The OR and CR rates using the combination therapy were higher than with either nivolumab or BV alone. In a cohort of the previously mentioned CheckMate039 study, patients with relapsed or refractory hematologic malignancies were treated with nivolumab and ipilimumab. For the patients with rrHL, the OR rate was 74% with a CR of 19%. Given the success of these combination therapies, as well as the similarities between cHL and PMBCL, several studies utilizing combination therapies in patients with PMBCL are underway. Additionally, given the high response rates in the relapsed or refractory setting, there are efforts to improve clinical outcomes by moving immune checkpoint inhibitors to the frontline setting.

Numerous clinical trials assessing combination therapies with pembrolizumab in B-cell lymphomas, including PMBCL, are underway. In one trial, patients with untreated DLBCL or grade 3b follicular lymphoma are being treated with frontline

| Trial Intervention                                      | Phase | Title                                                                 | Line of Treatment                        | ClinicalTrials.gov identifier | Status; Estimated completion date |
|---------------------------------------------------------|-------|----------------------------------------------------------------------|------------------------------------------|--------------------------------|-----------------------------------|
| Nivolumab with DA-REPOCH                                 | 2     | Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin’s Lymphoma | First-line                              | NCT03749018                    | Not yet recruiting;               |
| Nivolumab with combination chemotherapy                  | 1/2   | Nivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell Lymphoma | First-line                              | NCT03704714                    | Recruiting; June 2022              |
| Immunochemotherapy followed by Nivolumab maintenance     | 2     | Improving the Outcome of High-risk Aggressive B-cell Lymphoma Patients With Nivolumab Maintenance Therapy (NivoM) | First-line followed by maintenance therapy | NCT03569696                    | Not yet recruiting; July 2023     |
| Nivolumab and Ipilimumab prior to immunotransplant       | 1/2   | Nivolumab/Ipilimumab-Primed Immunotransplant for DLBCL               | Relapsed and/or refractory              | NCT03305445                    | Recruiting; April 2020            |
| Nivolumab with Bendamustine, Gemcitabine, and Rituximab   | 1/2   | Safety and Efficacy of Bendamustine, Gemcitabine, Rituximab, Nivolumab [BeGeRN] in Patients With r/r DLBCL [BeGeRN] | Relapsed and/or refractory              | NCT03259529                    | Recruiting; December 2020         |
| Nivolumab and Copanlisib                                 | 2     | Copanlisib and Nivolumab in Treating Participants With Recurrent or Refractory Diffuse Large B-cell Lymphoma or Primary Mediastinal Large B-cell Lymphoma | Relapsed and/or refractory              | NCT03484819                    | Not yet recruiting; August 2020   |
| Nivolumab with Varlitumab                                 | 2     | Nivolumab With or Without Varlitumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas | Relapsed and/or refractory              | NCT03038672                    | Recruiting; December 2019         |

DLBCL, diffuse large B-cell lymphoma; NCT, ClinicalTrials.gov identifier; PMBCL, primary mediastinal large B-cell lymphoma; r/r, relapsed/refractory.
pembrolizumab and combination chemotherapy (ClinicalTrials.gov identifier: NCT02541565). In the relapsed/refractory setting, pembrolizumab is being given in combination with therapies such as tisagenlecleucel, vorinostat, ibrutinib, dendritic cell therapy and cryosurgery, and rituximab (Table 2). Several studies utilizing nivolumab combination therapies are also currently underway in both the frontline and relapsed or refractory settings (Table 3). Other studies targeting pathways unique to rrPMBCL, have been completed or are ongoing, including therapies targeting CD30 and the JAK/STAT pathway.\textsuperscript{76–78}

Other targeted therapies for relapsed/refractory PMBCL

As previously discussed, 80% of PMBCL expresses CD30 suggesting a potential benefit from therapy targeting CD30. BV, a chimeric CD30-specific IgG1 antibody conjugated to the microtubule-disrupting agent, monomethyl auristatin E (MMAE) is approved for cHL and anaplastic large B-cell lymphomas, both of which express CD30.\textsuperscript{75} Thus, a single-arm phase II trial looking at the use of BV in rrPMBCL patients was conducted.\textsuperscript{76} In this study, BV was administered at a dose of 1.8 mg per kg as a single IV infusion on day 1 of each 21-day cycle. A total of 15 patients were enrolled in five Italian centers with a median age of 29 years. Patients were heavily pretreated with a median of three prior treatments. Overall, 12 patients (80%) had disease that was refractory to the last therapy prior to BV. All patients had received rituximab, eight patients (53%) received ASCT, and nine patients (60%) received radiation. The OR rate was 13.3% (2/15) with no patients achieving a CR. Overall, two patients achieved a PR and one patient had SD. The remaining 12 patients (80%) had progression of disease. Given this low OR rate, the study was terminated early.

As mentioned previously, another potential therapeutic target in PMBCL is the JAK/STAT pathway. The JAK2 2 inhibitor, ruxolitinib, and the JAK2/FLT3 inhibitor, SB518, have both been evaluated in HL and PMBCL. However, no conclusion has been made regarding their efficacy due to the low number of cases thus far.\textsuperscript{77,78}

Conclusion

PMBCL is distinctly different from other mature B-cell lymphomas and further studies of effective salvage therapies are needed. Although classified as a subtype of DLBCL, PMBCL is clinically, genetically, and molecularly different from other mature B-cell lymphomas and shares many common features with cHL. Relapsed/refractory PMBCL has a dismal prognosis and consequently attention has been aimed at curative therapy in the frontline setting. With the institution of infusion regimens like DA-REPOCH, more than 90% of patients are cured. Few studies have looked at the efficacy of salvage regimens in rrPMBCL. Commonly used salvage therapies have been similar to those used for DLBCL such as DHAP, ESHAP, GDP, transplant, and more. Several small retrospective studies have shown poor response rates of only up to 25% with these therapies. The genetics of PMBCL are similar to cHL, which suggests that it may respond better to therapies traditionally used in cHL. Pembrolizumab has shown efficacy to cHL and is approved for the treatment of relapsed/refractory HL. Initial phase I and IIb studies assessing its efficacy in rrPMBCL have shown response rates of 41%. Additionally, pembrolizumab is well tolerated with few grade 3 or 4 adverse events. Additionally, combination therapies utilizing pembrolizumab may increase the efficacy and response rate and are currently underway.

Funding

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Conflict of interest statement

The authors declare that there is no conflict of interest.

ORCID iD

Robert Chen https://orcid.org/0000-0002-2714-2434

References

1. Philip T, Guglielmi C, Hagenbeck A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. \textit{N Engl J Med} 1995; 333: 1540–1545.

2. Lazzarino M, Orlandi E, Paulli M, et al. Treatment outcome and prognostic factors for primary mediastinal (thymic) B-cell lymphoma: a multicenter study of 106 patients. \textit{J Clin Oncol} 1997; 15: 1646–1653.
3. Lichtenstein AK, Levine A, Taylor CR, et al. Primary mediastinal lymphoma in adults. Am J Med 1980; 68: 509–514.

4. Miller JB, Variakojis D, Bitran JD, et al. Diffuse histiocytic lymphoma with sclerosis: a clinicopathologic entity frequently causing superior venacaval obstruction. Cancer 1981; 47: 748–756.

5. Levitt LJ, Aisenberg AC, Harris NL, et al. Primary non-Hodgkin's lymphoma of the mediastinum. Cancer 1982; 50: 2486–2492.

6. Yousem SA, Weiss LM and Warnke RA. Primary mediastinal non-Hodgkin's lymphomas: a morphologic and immunologic study of 19 cases. Am J Clin Pathol 1985; 83: 676–680.

7. Moller P, Moldenhauer G, Momburg F, et al. Mediastinal lymphoma of clear cell type is a tumor corresponding to terminal steps of B cell differentiation. Blood 1987; 69: 1087–1095.

8. Harris N, Jaffe E, Stein H, et al. A revised European–American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361–1392.

9. Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. In: Primary mediastinal (thymic) large B-cell lymphoma. Lyon, France: IARC Press, 2008, pp. 250–251.

10. National Cancer Institute: SEER Cancer Statistics. Cancer stat facts: Hodgkin lymphoma, https://seer.cancer.gov/statfacts/html/hodg.html (2014, accessed 11 November 2018).

11. Cazals-Hatem D, Lepage E, Brice P, et al. Primary mediastinal large B-cell lymphoma: a clinicopathologic study of 141 cases compared with 916 nonmediastinal large B-cell lymphomas, a GELA (Groupe d’Etude des Lymphomes de l’Adulte) study. Am J Surg Pathol 1996; 20: 877–888.

12. Armitage JO and Weisenburger DD. New approach to classifying non-Hodgkin’s lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin’s Lymphoma Classification Project. J Clin Oncol 1998; 16: 2780–2795.

13. Addis BJ and Isaacson PG. Large cell lymphoma of the mediastinum: a B-cell tumor of probable thymic origin. Histopathology 1986; 10: 379–390.

14. Menestrina F, Chilosi M, Bonetti F, et al. Mediastinal large-cell lymphomas of B-type, with sclerosis: histopathological and immunohistochemical study of eight cases. Histopathology 1986; 10: 589–600.

15. Lazzarino M, Orlandi E, Pauli M, et al. Primary mediastinal B-cell lymphoma with sclerosis: an aggressive tumor with distinctive clinical and pathologic features. J Clin Oncol 1993; 11: 2306–2313.

16. Bishop PC, Wilson WH, Pearson D, et al. CNS involvement in primary mediastinal large B-cell lymphoma. J Clin Oncol 1999; 17: 2479–2485.

17. Pileri SA, Gaidano G, Zinzani PL, et al. Primary mediastinal B-cell lymphoma: high frequency of BCL-6 mutations and consistent expression of the transcription factors OCT-2, BOB.1, and PU.1 in the absence of immunoglobulins. Am J Pathol 2003; 162: 243–253.

18. Higgins JP and Warnke RA. CD30 expression is common in mediastinal large B-cell lymphoma. Am J Clin Pathol 1999; 112: 241–247.

19. Pileri SA, Zinzani PL, Gaidano G, et al.; International Extranodal Lymphoma Study Group. Pathobiology of primary mediastinal B-cell lymphoma. Leuk Lymphoma 2003; 44(Suppl. 3): S21–S26.

20. Savage KJ, Monti S, Kutok JL, et al. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood 2003; 102: 3871–3879.

21. Rosenwald A, Wright G, Leroy K, et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med 2003; 198: 851–862.

22. Calvo KR, Traverse-Glehen A, Pittaluga S, et al. Molecular profiling provides evidence of primary mediastinal large B-cell lymphoma as a distinct entity related to classic Hodgkin lymphoma: implications for mediastinal gray zone lymphomas as an intermediate form of B-cell lymphoma. Adv Anat Pathol 2004; 11: 227–238.

23. Zinzani PL, Martelli M, Magagnoli M, et al. Treatment and clinical management of primary mediastinal large B-cell lymphoma with sclerosis: MACOP-B regimen and mediastinal radiotherapy monitored by (67) Gallium scan in 50 patients. Blood 1999; 94(1): 3289–3293.

24. Zinzani PL, Martelli M, Bendandi M, et al. Primary mediastinal large B-cell lymphoma with sclerosis: a clinical study of 89 patients treated
with MACOP-B chemotherapy and radiation therapy. *Haematologica* 2001; 86: 187–191.

25. Dunleavy K and Bollard CM. Sobering realities of surviving Hodgkin lymphoma. *Blood* 2011; 117: 1772–1773.

26. Swerdlow AJ, Cooke R, Bates A, et al. Breast cancer risk after supradiaphragmatic radiotherapy for Hodgkin’s lymphoma in England and Wales: A National Cohort Study. *J Clin Oncol* 2012; 30: 2745–2742.

27. Dunleavy K, Pittaluga S, Maeda LS, et al. Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. *N Engl J Med* 2013; 368: 1408–1416.

28. Kuruulla J, Pintilie M, Tsang R, et al. Salvage chemotherapy and autologous stem cell transplantation are inferior for relapsed or refractory primary mediastinal large B-cell lymphoma compared with diffuse large B-cell lymphoma. *Leuk Lymphoma* 2008; 49: 1329–1336.

29. Hamlin PA, Portlock CS, Straus DJ, et al. Primary mediastinal large B-cell lymphoma: optimal therapy and prognostic factor analysis in 141 consecutive patients treated at memorial Sloan Kettering from 1980 to 1999. *Br J Haematol* 2005; 130: 691–699.

30. Sehn LH, Antin JH, Shulman LN, et al. Primary diffuse large B-cell lymphoma of the mediastinum: outcome following high-dose chemotherapy and autologous hematopoietic cell transplantation. *Blood* 1998; 91: 717–723.

31. Aoki T, Shimada K, Suzuki R, et al. High-dose chemotherapy followed by autologous stem cell transplantation for relapsed/refractory primary mediastinal large B-cell lymphoma. *Blood Cancer J.* 2015; 5: e372.

32. Joos S, Otano-Joos MI, Ziegler S, et al. Primary mediastinal (thymic) B-cell lymphoma is characterized by gains of chromosomal material including 9p and amplification of the REL gene. *Blood* 1996; 87: 1571–1578.

33. Joos S, Granzow M, Holtgreve-Grez H, et al. Hodgkin’s lymphoma cell lines are characterized by frequent aberrations on chromosomes 2p and 9p including REL and JAK2. *Int J Cancer* 2003; 103: 489–495.

34. Bentz M, Barth TF, Bruderlein S, et al. Gain of chromosome arm 9p is characteristic of primary mediastinal B-cell lymphoma (MBL): comprehensive molecular cytogenetic analysis and presentation of a novel MBL cell line. *Genes Chromosomes Cancer* 2001; 30: 393–401.

35. Green MR, Monti S, Rodig SJ, et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. *Blood* 2010; 116: 3268–3277.

36. Shi M, Roemer MG, Chapuy B, et al. Expression of programmed cell death 1 ligand 2 (PD-L2) is a distinguishing feature of primary mediastinal (thymic) large B-cell lymphoma and associated with PDCD1LG2 copy gain. *Am J Surg Pathol* 2014; 38: 1715–1723.

37. Prochazka V, Papajik T, Flodr F, et al. Programmed death-1 ligand is uniformly expressed on primary mediastinal diffuse large b-cell lymphoma cells with no influence on patient survival. *Blood* 2012; 120: 2671.

38. Twa DD, Chan FC, Ben-Neriah S, et al. Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma. *Blood* 2014; 123: 2062–2065.

39. Menter T, Bodmer-Haeck A, Dirnhofer S, et al. Evaluation of the diagnostic and prognostic value of PD-L1 expression in Hodgkin and B-cell lymphomas. *Hum Pathol* 2016; 54: 17–24.

40. Tanaka Y, Maeshima AM, Nomoto J, et al. Expression pattern of PD-L1 and PD-L2 in classical Hodgkin lymphoma, primary mediastinal large B-cell lymphoma, and gray zone lymphoma. *Eur J Haematol* 2018; 100: 511–517.

41. Andorsky DJ, Yamada RE, Said J, et al. Programmed death ligand 1 is expressed by non-Hodgkin lymphomas and inhibits the activity of tumor associated T cells. *Clin Cancer Res* 2011; 17: 4232–4244.

42. Vainchenker W and Constantinescu SN. JAK/STAT signaling in hematological malignancies. *Oncogene* 2013; 32: 2601–2613.

43. Guiter C, Dusantier-Fourt I, Copie-Bergman C, et al. Constitutive STAT6 activation in hematological malignancies. *Blood* 2010; 116: 3268–3277.

44. Hao Y, Chapuy B, Monti S, et al. Selective JAK2 inhibition specifically decreases Hodgkin lymphoma growth in vitro and in vivo. *Clin Cancer Res* 2014; 20: 2674–2683.

45. Ishida Y, Agata Y, Shibahara K, et al. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. *EMBO J* 1992; 11: 3887–3895.
46. Agata Y, Kawasaki A, Nishimura H, et al. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol 1996; 8: 765–772.

47. Nishimura H, Nose M, Haii H, et al. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 1999; 11: 141–151.

48. Dong H, Zhu G, Tamada K, et al. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med 1999; 5: 1365–1369.

49. Freeman GJ, Long AJ, Iwai Y, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000; 192: 1027–1034.

50. Keir ME, Butte MJ, Freeman GJ, et al. PD-1 and its ligands in tolerance and immunity. Ann Rev Immunol 2008; 26: 677–704.

51. Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002; 8: 793–800.

52. Iwai Y, Ishida M, Tanaka Y, et al. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA 2002; 99: 12293–12297.

53. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012; 366: 2455–2465.

54. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366: 2443–2454.

55. Patnaik A, Kang SP, Rasco D, et al. Phase I study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in patients with advanced solid tumors. Clin Cancer Res 2015; 21: 4286–4293.

56. Robert C, Ribas A, Wolchok JD, Hodi FS, Hamid O, Keeford R, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab inipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. The Lancet, 2014; 384: 1109–1117.

57. Chen R, Zinzani PL, Fanale MA, et al. Phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic Hodgkin lymphoma. J Clin Oncol 2017; 35: 2125–2132.

58. Yamamoto R, Nishikori M, Kitawaki T, et al. PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma. Blood 2008; 111: 3220–3224.

59. Assel SM, Lesokhin AM, Borrello I, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N Engl J Med 2015; 372: 311–319.

60. Younes A, Santoro A, Shipp M, et al. Nivolumab for classical Hodgkin’s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol 2016; 17: 1283–1294.

61. Zinzani PL, Ribrag V, Moskowitz CH, et al. Phase 1b study of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma: results from the ongoing keynote-013 trial. Blood 2016: 128: 619.

62. Freshwater T, de Greef R, Kondic A, et al. Assessment of pembrolizumab (MK-3475) dosing strategy based on population pharmacokinetics and exposure-response models. J Pharmacokinet Pharmacodynam 2015; 42: S15.

63. Zinzani PL, Ribrag V, Moskowitz CH, et al. Safety & tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma. Blood 2017; 130: 267–270.

64. Zinzani PL, Thieblemont C, Melnichenko V, et al. Efficacy and safety of pembrolizumab in relapsed/refractory primary mediastinal large B-cell lymphoma. Blood 2017; 130: 267–270.

65. Ma SD, Xu X, Jones R, et al. PD-1/CTLA-4 blockade inhibits Epstein-Barr virus-induced lymphoma growth in a cord blood humanized-mouse model. PLoS Pathog 2016; 12: e1005642.

66. Selby M, Engelhardt J, Lu L-S, et al. Antitumor activity of concurrent blockade of immune checkpoint molecules CTLA-4 and PD-1 in preclinical models. J Clin Oncol. 2013; 31(Suppl): 3061.

67. Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013; 369: 122–133.

68. Larkin JM, Hodi FS, Wolchok JD, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015; 373: 23–34.

69. Robert J, Motzer MD, Nizar M, et al. Nivolumab plus ipilimumab versus sunitinib in advanced
renal-cell carcinoma. *N Engl J Med* 2018; 378: 1277–1290.

70. Horn L, Mansfield AS, Szczęsna A, *et al.* First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. *N Engl J Med* 2018; 379: 2220–2229.

71. Diefenbach CS, Hong F, David K, *et al.* Safety and efficacy of combination of brentuximab vedotin and nivolumab in relapsed/refractory Hodgkin lymphoma: a trial of the ECOG-ACRIN Cancer Research Group (E4412). *Hematol Oncol* 2017; 35(Suppl. 2): 84–85.

72. Herrera AF, Moskowitz AJ, Bartlett NL, *et al.* Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma. *Blood* 2018; 131: 1183–1194.

73. Younes A, Gopal AK, Smith SE, *et al.* Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. *J Clin Oncol* 2012; 30: 2183–2189.

74. Ansell S, Gutierrez ME, Shipp MA, *et al.* A phase 1 study of nivolumab in combination with ipilimumab for relapsed or refractory hematologic malignancies (CheckMate 039) [abstract]. *Blood* 2016; 128: abstract 183.

75. de Claro RA, McGinn K, Kwitkowski V, *et al.* US Food and Drug Administration approval summary: brentuximab vedotin for the treatment of relapsed Hodgkin lymphoma or relapsed systemic anaplastic large-cell lymphoma. *Clin Cancer Res* 2012; 18: 5845–5849.

76. Zinzani PL, Pellegrini C, Chiappella A, *et al.* Brentuximab vedotin in relapsed primary mediastinal large B-cell lymphoma: results from a phase 2 clinical trial. *Blood* 2017; 129: 2328–2330.

77. Younes A, Romaguera J, Fanale M, *et al.* Phase I study of novel oral Janus kinase 2 inhibitor, SB1518, in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypes. *J Clin Oncol* 2012; 30: 4161–4167.

78. Kim SJ, Kang HJ, Dong-Yeop S, *et al.* The efficacy on JAK2 inhibitor in heavily pretreated classical Hodgkin lymphoma: a prospective pilot study of ruxolitinib in relapsed or refractory classical Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. *Blood* 2016; 128: 1820.